Factors Associated With the Development of Brain Metastases Analysis of 975 Patients With Early Stage Nonsmall Cell Lung Cancer

Basit Öğe Kaydı
dc.contributor.authorHubbs, Jessica L.
dc.contributor.authorBoyd, Jessamy A.
dc.contributor.authorHollis, Donna
dc.contributor.authorChino, Junzo P.
dc.contributor.authorSaynak, Mert
dc.contributor.authorKelsey, Chris R.
dc.date.accessioned2024-06-12T11:09:19Z
dc.date.available2024-06-12T11:09:19Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBACKGROUND The risk of developing brain metastases after definitive treatment of locally advanced nonsmall cell lung cancer (NSCLC) is approximately 30%-50%. The risk for patients with early stage disease is less defined. The authors sought to investigate this further and to study potential risk factors. METHODS The records of all patients who underwent surgery for T1-T2 N0-N1 NSCLC at Duke University between the years 1995 and 2005 were reviewed. The cumulative incidence of brain metastases and distant metastases was estimated by using the Kaplan-Meier method. A multivariate analysis assessed factors associated with the development of brain metastases. RESULTS Of 975 consecutive patients, 85% were stage I, and 15% were stage II. Adjuvant chemotherapy was given to 7%. The 5-year actuarial risk of developing brain metastases and distant metastases was 10% (95% confidence interval [CI], 8-13) and 34% (95% CI, 30-39), respectively. Of patients developing brain metastases, the brain was the sole site of failure in 43%. On multivariate analysis, younger age (hazard ratio [HR], 1.03 per year), larger tumor size (HR, 1.26 per cm), lymphovascular space invasion (HR, 1.87), and hilar lymph node involvement (HR, 1.18) were associated with an increased risk of developing brain metastases. CONCLUSIONS In this large series of patients treated surgically for early stage NSCLC, the 5-year actuarial risk of developing brain metastases was 10%. A better understanding of predictive factors and biological susceptibility is needed to identify the subset of patients with early stage NSCLC who are at particularly high risk. Cancer 2010;116:5038-46. (C) 2010 American Cancer Societyen_US
dc.identifier.doi10.1002/cncr.25254
dc.identifier.endpage5046en_US
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.issue21en_US
dc.identifier.pmid20629035en_US
dc.identifier.scopus2-s2.0-78249232963en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage5038en_US
dc.identifier.urihttps://doi.org/10.1002/cncr.25254
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22771
dc.identifier.volume116en_US
dc.identifier.wosWOS:000283397700020en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCanceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNonsmall Cell Lung Canceren_US
dc.subjectBrain Metastasesen_US
dc.subjectPatterns Of Failureen_US
dc.subjectProphylactic Cranial Irradiationen_US
dc.subjectProphylactic Cranial Irradiationen_US
dc.subjectVinorelbine Plus Cisplatinen_US
dc.subjectOncology Group Rtogen_US
dc.subjectPrognostic-Factorsen_US
dc.subjectMultivariate-Analysisen_US
dc.subjectCerebral Metastasisen_US
dc.subjectSurgical Resectionen_US
dc.subjectFailure Patternsen_US
dc.subjectRandomized-Trialen_US
dc.subjectVessel Invasionen_US
dc.titleFactors Associated With the Development of Brain Metastases Analysis of 975 Patients With Early Stage Nonsmall Cell Lung Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu